chartexchange

ARIA
Aria Opportunities ETF
stockNYSEETF

At CloseNov 16, 2026 3:41:31 PM EST
21.02USD0.000%(0.00)34
After-hoursNov 18, 2026 4:10:30 PM EST
20.40USD-2.943%(-0.62)
Loading…
Loading…
Sector
Healthcare
Industry
Drugs
Previous Close
$20.67
Beta
1.92
52-Week High
$26.76 2026-09-21
52-Week Low
$20.40 2026-11-18
SMA 50
$24.45
SMA 200
$18.11
Avg. Vol 10D
262
Avg. Vol 30D
362
Avg. Vol 90D
1.65M
Relative Vol
0.10
25.9900%
201
ARIA Profile

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

ARIA Performance
PeriodPriceDateChangeBeta
1W22.262026-11-12-8.18%1.110
1M23.872026-10-19-14.37%1.679
3M24.942026-08-19-18.04%1.904
6M25.332026-08-10-19.29%1.922
ARIA Stock Summary

Aria Opportunities ETF (NYSE:ARIA) stock price today is $20.44, and today's volume is 35. ARIA is down 1.129% today. The 30 day average volume is 362.